QIAGEN NV

QGEN50

$45.68arrow_drop_up0.04%$0.02

QGEN50

$45.68

arrow_drop_up0.04%$0.02

Performance History

Key Stats
Open	$45.85
Prev. Close	$45.66
EPS	0.35

Next Earnings Date	-
Dividend Yield %	-

	LOW	HIGH
Day Range	45.59	46.13
52 Week Range	34.74	47.44

Ratios







EPS	0.35

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About QIAGEN NV (QGEN)

QIAGEN NV (QGEN) is a leading global provider of molecular diagnostics and sample preparation technologies for academic, pharmaceutical, and biotechnology customers. The company offers a comprehensive portfolio of products and services that enable researchers to rapidly and accurately analyze DNA, RNA, and proteins. QIAGEN's products are used in a wide range of applications, including cancer research, infectious diseases, genetic testing, and personalized medicine. The company's innovative technologies and solutions have been instrumental in advancing our understanding of diseases and improving patient care. With a market cap of over $12 billion, QIAGEN is a well-established player in the life sciences industry.

QIAGEN has a strong financial position and has consistently delivered solid financial results. The company reported revenue of $1.53 billion in 2020, representing a 16% increase compared to the previous year. QIAGEN's net income for the same period was $290 million, reflecting a 26% growth. The strong financial performance is a testament to QIAGEN's ability to effectively address the evolving needs of its customers and capitalize on emerging opportunities. QIAGEN has a diverse customer base, including academic institutions, pharmaceutical companies, and diagnostic laboratories, which provides a significant revenue stream and reduces dependence on any single segment or customer.

Websitecall_made

Sector: Healthcare
Industry: Diagnostics & Research
CEO: Mr. Thierry Bernard
Headquarters: Venlo
Employees: 6200
Exchange: NYSE

Keep an eye on QIAGEN NV

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is QIAGEN NV's (QGEN) price per share?

The current price per share for QIAGEN NV (QGEN) is $45.68. The stock has seen a price change of $0.02 recently, indicating a 0.04% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for QIAGEN NV (QGEN)?

For QIAGEN NV (QGEN), the 52-week high is $47.44, which is 3.85% from the current price. The 52-week low is $34.74, the current price is 31.49% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is QIAGEN NV (QGEN) a growth stock?

QIAGEN NV (QGEN) has shown an average price growth of 0.41% over the past three years. It has received a score of 43 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying QIAGEN NV as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is QIAGEN NV (QGEN) stock price performance year to date (YTD)?

As of the latest data, QIAGEN NV (QGEN) has a year-to-date price change of 1.51%. Over the past month, the stock has experienced a price change of -2.71%. Over the last three months, the change has been 4.46%. Over the past six months, the figure is 3.49%. Looking at a longer horizon, the five-year price change stands at 29.83%.

help

Is QIAGEN NV (QGEN) a profitable company?

QIAGEN NV (QGEN) has a net income of $341.3M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 62.23% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -32.31% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $1.97B, although specific revenue growth data is currently not available. The gross profit is $1.22B. Operating income is noted at $445.25M. Furthermore, the EBITDA is $723.86M.

help

What is the market capitalization of QIAGEN NV (QGEN)?

QIAGEN NV (QGEN) has a market capitalization of $10.15B. The average daily trading volume is 1.35M, indicating the stock's liquidity and investor engagement.

News

MOLECULAR DIAGNOSTICS

MALARIA

DENGUE

9/13/2024

Can QGEN Stock Gain From the Expanded Bio-Manguinhos/Fiocruz Alliance?

LIQUID BIOPSY

CANCER DIAGNOSTICS

NEXT-GENERATION SEQUENCING

NORTH AMERICA

MARKET GROWTH

9/13/2024

Liquid Biopsy Market to Reach $ 32.54 Billion, Globally, by 2033 at 11.61% CAGR: The Brainy Insights

qPCR Reagents - Global Market Trends, Competitive Analysis, and Business Opportunities to 2030 - Surge in Demand in Oncology & Genetic Screening and Drug Discovery Programs

Breast Biopsy Research Analysis Report 2024 - Global Market to Reach $2.08 Billion - Rising Momentum of Liquid Biopsy, Incorporation of Minimally Invasive Breast Biopsies